Cellular immune responses of BALB/c mice induced by intramuscular injection of PRRSV-ORF5 DNA vaccine with different doses

The urgent need for effective, safe and equitably accessible vaccines to tackle the ongoing spread of COVID-19 led researchers to generate vaccine candidates targeting varieties of immunogens of SARS-CoV-2. Because of its crucial role in mediating binding and entry to host cell and its proven safety profile, the subunit 1 (S1) of the spike protein represents an attractive immunogen for vaccine development. Here, we developed and assessed the immunogenicity of a DNA vaccine encoding the SARS-CoV-2 S1. Following in vitro confirmation and characterization, the humoral and cellular immune responses of our vaccine candidate (pVAX-S1) was evaluated in BALB/c mice using two different doses, 25 µg and 50 µg. Our data showed high levels of SARS-CoV-2 specific IgG and neutralizing antibodies in mice immunized with three doses of pVAX-S1. Analysis of the induced IgG subclasses showed a Th1-polarized immune response, as demonstrated by the significant elevation of spike-specific IgG2a and IgG2b, compared to IgG1. Furthermore, we found that the immunization of mice with three doses of 50 µg of pVAX-S1 could elicit significant memory CD4+ and CD8+ T cell responses. Taken together, our data indicate that pVAX-S1 is immunogenic and safe in mice and is worthy of further preclinical and clinical evaluation.

Download Full-text

Cellular and humoral immunogenicity of a candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1

10.20944/preprints202106.0650.v1 ◽

2021 ◽

Author(s):

Khalid A. Alluhaybi ◽

Rahaf H. Alharbi ◽

Rowa Y. Alhabbab ◽

Najwa D Aljehani ◽

Sawsan S. Alamri ◽

...

Keyword(s):

Immune Responses ◽

Dna Vaccine ◽

Neutralizing Antibodies ◽

Vaccine Development ◽

Cell Responses ◽

Cellular Immune Responses ◽

Specific Igg ◽

Cellular Immune ◽

Different Doses

The urgent need for effective, safe and equitably accessible vaccines to tackle the ongoing spread of COVID-19 led researchers to generate vaccine candidates targeting varieties of immunogens of SARS-CoV-2. Because of its crucial role in mediating binding and entry to host cell and its proven safety profile, the subunit 1 (S1) of the spike protein represents an attractive immunogen for vaccine development. Here, we developed and assessed the immunogenicity of a DNA vaccine encoding the SARS-CoV-2 S1. Following in vitro confirmation and characterization, the humoral and cellular immune responses of our vaccine candidate (pVAX-S1) was evaluated in BALB/c mice using two different doses, 25 µg and 50 µg. Our data showed high levels of SARS-CoV-2 specific IgG and neutralizing antibodies in mice immunized with three doses of pVAX-S1. Analysis of the induced IgG subclasses showed a Th1-polarized immune response as demonstrated by the significant elevation of spike-specific IgG2a and IgG2b compared to IgG1. Furthermore, we found that immunization of mice with three doses of 50 µg of pVAX-S1 could elicit significant memory CD4+ and CD8+ T cell responses. Taken together, our data indicates that pVAX-S1 is immunogenic and safe in mice and is worthy of further preclinical and clinical evaluation.

Download Full-text

A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs

Vaccine ◽

10.1016/j.vaccine.2016.05.030 ◽

2016 ◽

Vol 34 (32) ◽

pp. 3634-3640 ◽

Cited By ~ 8

Author(s):

Marie Borggren ◽

Jens Nielsen ◽

Ingrid Karlsson ◽

Tina S. Dalgaard ◽

Ramona Trebbien ◽

...

Keyword(s):

Immune Responses ◽

Dna Vaccine ◽

Cellular Immune Responses ◽

Intradermal Delivery ◽

Cellular Immune

Download Full-text

Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine

Vaccine ◽

10.1016/j.vaccine.2008.07.052 ◽

2008 ◽

Vol 26 (49) ◽

pp. 6225-6231 ◽

Cited By ~ 28

Author(s):

Krystle A. Lang ◽

Jian Yan ◽

Ruxandra Draghia-Akli ◽

Amir Khan ◽

David B. Weiner

Keyword(s):

Immune Responses ◽

Dna Vaccine ◽

Rhesus Macaques ◽

Hcv Genotype ◽

Cellular Immune Responses ◽

Genotype 1A ◽

Cellular Immune

Download Full-text

Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting

Vaccine ◽

10.1016/j.vaccine.2004.10.013 ◽

2005 ◽

Vol 23 (14) ◽

pp. 1649-1656 ◽

Cited By ~ 19

Author(s):

He Xiao-wen ◽

Sun Shu-han ◽

Hu Zhen-lin ◽

Li Jun ◽

Jiang Lei ◽

...

Keyword(s):

Hepatitis B ◽

Immune Responses ◽

Dna Vaccine ◽

Cellular Immune Responses ◽

Cellular Immune

Download Full-text

Intramuscular Delivery of Adenovirus Serotype 5 Vector Expressing Humanized Protective Antigen Induces Rapid Protection against Anthrax That May Bypass Intranasally Originated Preexisting Adenovirus Immunity

Clinical and Vaccine Immunology ◽

10.1128/cvi.00560-13 ◽

2013 ◽

Vol 21 (2) ◽

pp. 156-164 ◽

Cited By ~ 6

Author(s):

Shipo Wu ◽

Zhe Zhang ◽

Rui Yu ◽

Jun Zhang ◽

Ying Liu ◽

...

Keyword(s):

Immune Responses ◽

Intramuscular Injection ◽

Protective Antigen ◽

Lethal Dose ◽

Adenovirus Serotype ◽

Cellular Immune Responses ◽

Intramuscular Inoculation ◽

Serotype 5 ◽

Cellular Immune ◽

Induced Immunity

ABSTRACTDeveloping an effective anthrax vaccine that can induce a rapid and sustained immune response is a priority for the prevention of bioterrorism-associated anthrax infection. Here, we developed a recombinant replication-deficient adenovirus serotype 5-based vaccine expressing the humanized protective antigen (Ad5-PAopt). A single intramuscular injection of Ad5-PAopt resulted in rapid and robust humoral and cellular immune responses in Fisher 344 rats. Animals intramuscularly inoculated with a single dose of 108infectious units of Ad5-PAopt achieved 100% protection from challenge with 10 times the 50% lethal dose (LD50) of anthrax lethal toxin 7 days after vaccination. Although preexisting intranasally induced immunity to Ad5 slightly weakened the humoral and cellular immune responses to Ad5-PAopt via intramuscular inoculation, 100% protection was achieved 15 days after vaccination in Fisher 344 rats. The protective efficacy conferred by intramuscular vaccination in the presence of preexisting intranasally induced immunity was significantly better than that of intranasal delivery of Ad5-PAopt and intramuscular injection with recombinant PA and aluminum adjuvant without preexisting immunity. As natural Ad5 infection often occurs via the mucosal route, the work here largely illuminates that intramuscular inoculation with Ad5-PAopt can overcome the negative effects of immunity induced by prior adenovirus infection and represents an efficient approach for protecting against emerging anthrax.

Download Full-text

Antitumor Effect of a DNA Vaccine Harboring Prostate Cancer-Specific Antigen with IL-12 as an Intramolecular Adjuvant

Journal of Molecular Microbiology and Biotechnology ◽

10.1159/000477245 ◽

2017 ◽

Vol 27 (3) ◽

pp. 168-174 ◽

Cited By ~ 1

Author(s):

Yu Yang ◽

Zhiqiang Shao ◽

Jiangping Gao

Keyword(s):

Prostate Cancer ◽

Immune Responses ◽

Dna Vaccine ◽

Dna Vaccines ◽

Electric Pulse ◽

Specific Antigen ◽

Interleukin 12 ◽

Cellular Immune Responses ◽

Prostate Cancer Therapy ◽

Cellular Immune

To improve the lower immune intensity of DNA vaccines, we developed a DNA vaccine based on prostate cancer-specific antigen (PSA), which has been suggested as a potential target for prostate cancer therapy, and enhanced the DNA vaccine potency using interleukin-12 (IL-12) as an intramolecular adjuvant. A series of DNA plasmids encoding human PSA, IL-12, and their conjugates was constructed and injected into female mice intramuscularly, followed by an electric pulse. The humoral and cellular immune responses after immunization were detected by ELISA and ELISPOT, respectively. To evaluate the therapeutic efficacy of these plasmids, a mouse model with a PSA-expressing tumor was constructed. Mice vaccinated with PSA-IL-12 plasmids elicited the strongest PSA-specific humoral and cellular immune responses. Furthermore, these vaccinations inhibited the growth of PSA-expressing tumors and prolonged mouse survival. These observations emphasize the potential of the IL-12 gene as an intramolecular adjuvant for DNA vaccines. Moreover, the vaccine based on PSA and IL-12 may be a promising treatment for prostate cancer.

Download Full-text